Patents Examined by Michael Burkhart
  • Patent number: 9464140
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 11, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 9453217
    Abstract: Antigen-specific immunoglobulin V-regions are identified from a library of nucleic acids amplified using polymerase chain reaction using leader sequence-specific forward primers. The use of leader sequence primers allows all V-region sequences to be amplified (including those with extensive 5? end mutations) without loss of the original 5? V gene segment sequence. These libraries can be screened for antigen-specific V-regions using eukaryotic cells engineered to express the amplified V-region-encoding nucleic acids or using bacterial phage display techniques. In the latter, a second V-region library is made using a larger than conventional set of 5? V-region primers. The sequence errors introduced into the amplification products by this method are corrected using sequence information obtained in the products amplified by the V-region primers to screen the library created using the leader sequence primers.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: September 27, 2016
    Assignee: XBIOTECH, INC.
    Inventor: John Simard
  • Patent number: 9428580
    Abstract: The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: August 30, 2016
    Assignee: ARGEN-X B.V.
    Inventors: Torsten Dreier, Christophe Frederic Jerome Blanchetot, Johannes Joseph Wilhelmus De Haard
  • Patent number: 9428768
    Abstract: The present invention relates to improved methods for producing adenovirus compositions wherein host cells are grown in a bioreactor and purified by size partitioning purification to provide purified adenovirus compositions.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: August 30, 2016
    Assignee: Crucell Holland B.V.
    Inventors: Hai Pham, Shuyuan Zhang, Peter Clarke
  • Patent number: 9428766
    Abstract: The current invention reports a method for the recombinant production of a secreted heterologous immunoglobulin in a CHO cell comprising the following steps: i) providing a CHO cell, which is adapted to growth in suspension culture, adapted to growth in serum-free medium, mycoplasma free, and virus free, ii) providing a vector comprising a prokaryotic origin of replication, a first nucleic acid conferring resistance to a prokaryotic selection agent, a second nucleic acid encoding the heavy chain of said heterologous immunoglobulin, a third nucleic acid encoding the light chain of said heterologous immunoglobulin, a fourth nucleic acid conferring resistance to a eukaryotic selection agent, iii) transfecting said CHO cell, wherein said transfecting comprises a) transfecting said CHO cell with said vector comprising a fourth nucleic acid conferring resistance to a first eukaryotic selection agent, b) selecting a CHO cell by growth in cultivation medium containing said first eukaryotic selection agent, c) transfe
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: August 30, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Goepfert, Hendrik Knoetgen, Erhard Kopetzki, Anne Stern
  • Patent number: 9409959
    Abstract: The present invention provides silk proteins, as well as nucleic acids encoding these proteins. The present invention also provides recombinant cells and/or organisms which synthesize silk proteins. Silk proteins of the invention can be used for a variety of purposes such as in the manufacture of personal care products, plastics, textiles, and biomedical products.
    Type: Grant
    Filed: October 4, 2006
    Date of Patent: August 9, 2016
    Assignee: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Tara D. Sutherland, Victoria S. Haritos, Holly Trueman, Alagacone Sriskantha, Sarah Weisman, Peter M. Campbell
  • Patent number: 9399671
    Abstract: The invention relates to a transcriptionally active recombinant linear polynucleotide encoding a multimeric protein comprising in the following order, a first promoter sequence, a first encoding polynucleotide sequence, a bidirectional regulatory sequence, a second encoding polynucleotide sequence and a second promoter sequence, wherein the first and second encoding polynucleotide sequences are in convergent transcriptional orientation, each encoding polynucleotide sequence encodes a component of the multimeric protein and the bidirectional regulatory sequence is operably linked to the first and second encoding polynucleotide sequences and the multimeric protein is an antibody or fragment thereof and each encoding polynucleotide sequence encodes one or more antibody domains or fragments thereof.
    Type: Grant
    Filed: February 25, 2010
    Date of Patent: July 26, 2016
    Assignee: UCB PHARMA S.A.
    Inventors: Mark Ellis, Laura Ellen Newnham
  • Patent number: 9394536
    Abstract: Antigen-specific immunoglobulin V-regions are identified from a library of nucleic acids amplified using polymerase chain reaction using leader sequence-specific forward primers. The use of leader sequence primers allows all V-region sequences to be amplified (including those with extensive 5? end mutations) without loss of the original 5? V gene segment sequence. These libraries can be screened for antigen-specific V-regions using eukaryotic cells engineered to express the amplified V-region-encoding nucleic acids or using bacterial phage display techniques. In the latter, a second V-region library is made using a larger than conventional set of 5? V-region primers. The sequence errors introduced into the amplification products by this method are corrected using sequence information obtained in the products amplified by the V-region primers to screen the library created using the leader sequence primers.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: July 19, 2016
    Assignee: XBIOTECH, INC.
    Inventor: John Simard
  • Patent number: 9394546
    Abstract: The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment into Pichia sp. yeast, a method for producing an immunoglobulin Fc fragment comprising culturing the transformant, and recovering the immunoglobulin Fc fragment from the culture, and an immunoglobulin Fc fragment, prepared by the above method for use as a drug carrier. The transformant is suggested as a solution to the problems associated with the use of E. coli or animal cells as hosts for producing immunoglobulin Fc fragments useful as drug carriers, so that it can find various applications in the effective and economical production of drugs.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: July 19, 2016
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Jin-Sun Kim, Yong Ho Huh, Euh Lim Oh, Min Young Kim, Sung Youb Jung, Se Chang Kwon
  • Patent number: 9388429
    Abstract: The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: July 12, 2016
    Assignee: GenVec, Inc.
    Inventors: Jason G. D. Gall, Douglas E. Brough, C. Richter King
  • Patent number: 9376685
    Abstract: Disclosed herein are linear donor molecules comprising homology arms of 50-750 base pairs (e.g., 50-100 base pairs) flanking one or more sequences of interest. The donor molecules and/or compositions comprising these molecules can be used in methods for targeted integration of an exogenous sequence into a specified region of interest in the genome of a cell.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: June 28, 2016
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Russell DeKelver, Philip D. Gregory, Michael C. Holmes, Fyodor Urnov
  • Patent number: 9358286
    Abstract: The invention provides means and methods for producing one or more Ig-like molecules in a single host cell. Novel CH3 mutations enabling the production of monospecific and/or bispecific Ig-like molecules of interest are also provided.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: June 7, 2016
    Assignee: Merus B.V.
    Inventors: Cornelis A. De Kruif, Linda Johanna Aleida Hendriks, Ton Logtenberg
  • Patent number: 9353151
    Abstract: An HLA-binding peptide binding to a HLA-A type molecule, the HLA-binding peptide includes at least one type of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 80, and consists of not less than 8 and not more than 11 amino acid residues. All of these amino acid sequences herein mentioned are the predicted amino acid sequences binding to a human HLA-A type molecule with the prediction program using the certain active learning method.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: May 31, 2016
    Assignees: NEC CORPORATION, KOCHI UNIVERSITY
    Inventors: Tomoya Miyakawa, Keiko Udaka
  • Patent number: 9346891
    Abstract: The invention relates to a platform technology for production of antigen binding polypeptides having specificity for a desired target antigen which is based on the conventional antibody repertoire of species in the family Camelidae, and to antigen binding polypeptides obtained using this technology platform. In particular, the invention provides an antigen binding polypeptide comprising a VH domain and a VL domain, wherein at least one hypervariable loop or complementarity determining region (CDR) in the VH domain or the VL domain is obtained from a VH or VL domain of a species in the family Camelidae.
    Type: Grant
    Filed: January 28, 2015
    Date of Patent: May 24, 2016
    Assignee: ARGEN-X.N.V.
    Inventors: Torsten Dreier, Christophe Frederic Jerome Blanchetot, Johannes Joseph Wilhelmus De Haard
  • Patent number: 9347936
    Abstract: The present invention provides an inactive Ca2+/calmodulin-dependent protein kinase II? (CaMKII?) knockin animal in which only the protein kinase activity of CaMKII? has been specifically impaired. Since CaMKII? is considered to be involved in higher brain functions including learning and memory, and inhibit epileptic seizure and brain disorders caused by ischemia, the inactive CaMKII? knockin animal of the present invention is widely usable for various studies of the brain and nerve, such as the studies of mechanisms of learning disability, dysmnesia, epileptic seizure and brain disorders.
    Type: Grant
    Filed: March 24, 2005
    Date of Patent: May 24, 2016
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Yoko Yamagata, Yuchio Yanagawa
  • Patent number: 9345787
    Abstract: The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing GM-CSF in a cell and increasing tumor specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing GM-CSF in a cell and increasing tumor specific immune response in a subject.
    Type: Grant
    Filed: December 21, 2009
    Date of Patent: May 24, 2016
    Assignee: Targovax Oy
    Inventors: Akseli Hemminki, Anna Kanerva, Vincenzo Cerullo, Sari Pesonen
  • Patent number: 9347087
    Abstract: Disclosed are methods, compositions and kits for the isolation of exosomes from biological fluids and tissues. Volume-excluding polymers are used to precipitate exosomes from biological samples thereby allowing exosome isolation by low-speed (benchtop) centrifugation or filtration. Further fractionation of exosomes after precipitation is also described.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: May 24, 2016
    Assignee: Life Technologies Corporation
    Inventors: Alexander Vlassov, Mu Li, Emily Zeringer, Richard Conrad
  • Patent number: 9326998
    Abstract: The invention relates to the use of viral inactivated-plasma cryoprecipitate concentrate (VIPCC) comprising a suitable fibronactin/fibrinogen ratio for treating a spine disease, disorder or condition such as intervertebral disc degeneration.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: May 3, 2016
    Assignee: Omrix Biopharmaceuticals Ltd.
    Inventors: Israel Nur, Liliana Bar, Edna Bechor
  • Patent number: 9328156
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: May 3, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
  • Patent number: 9321843
    Abstract: The present invention relates to the field of glycosylation engineering of proteins. More particularly, the present invention relates to glycosylation engineering to generate proteins with improved therapeutic properties, including antibodies with increased antibody-dependent cellular cytotoxicity.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: April 26, 2016
    Assignee: Roche Glycart AG
    Inventors: Pablo Umaña, Joël Jean-Mairet, James E. Bailey